If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.625    0.00 (0.00%)
Bid:
1.30
Ask:
2.30
Spread: 1.00 (76.923%)
Market Cap: £5.70m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director Dealing

31 Jul 2008 16:13

For Immediate Release 31 July 2008

PROTEOME SCIENCES plc

("Proteome Sciences" or the "Company")

PRESS RELEASE

DIRECTORS' SHAREHOLDINGS

Proteome Sciences announces that on 31 July 2008 it granted a conditional award of 1,882,500 Ordinary Shares of 1p each in the Company ("Ordinary Shares") to C.D.J. Pearce, Chief Executive and of 1,170,000 Ordinary Shares of 1p each to J.L. Malthouse, Finance Director, under its Long-Term Incentive Plan ("LTIP") based on a closing mid-market price on 30 July 2008 of 20p per Ordinary Share.

In accordance with the rules of the LTIP, the Ordinary Shares awarded will vest 3 years after the date of grant subject to the Company achieving a target total shareholder return (TSR) over a three-year performance period relative to the AIM Healthcare Index at the start of that period. TSR is the aggregate of share price growth and the value of dividend payments during the performance period. No shares will be released unless the Company's TSR performance exceeds that of the index, in which case 30% of the award will vest with full vesting only if the Company's TSR performance exceeds that of the Index by 10%, with a pro-rata award between 30% and 100% for each percentage point of out-performance up to 10%.

The Remuneration Committee of the Board of Directors believes that today's award under the LTIP aligns the interests of shareholders with those of the executive by making the award dependent on the success of management in delivering superior returns to shareholders.

C.D.J. Pearce currently holds 6,538,075 shares in the Company, and has a previous conditional award under the LTIP of up to 504,523 shares.

J.L. Malthouse currently holds 625,000 shares in the Company, and has a previous conditional award under the LTIP of up to 470,352 shares.

Ends

Proteome Sciences plc

Christopher Pearce James Malthouse

Chief Executive Officer Finance Director

christopher.pearce@proteomics.com james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Nominated Adviser

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes SpĴng Tel: +44 (0)20 7426 9000

vendor
Date   Source Headline
14th Aug 201810:03 amRNSDirector/PDMR Shareholding
9th Aug 20181:23 pmRNSDirector/PDMR Shareholding
2nd Aug 201810:03 amRNSDirector/PDMR Shareholding
31st Jul 20184:09 pmRNSDirector/PDMR Shareholding
27th Jul 201812:21 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSInterim Results
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20187:00 amRNSLoan Agreement and Notice of Results
18th Jun 20184:40 pmRNSSecond Price Monitoring Extn
18th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20181:36 pmRNSAGM Statement
24th Apr 20187:00 amRNSBoard Appointment
24th Apr 20187:00 amRNSPreliminary Results
3rd Apr 201810:40 amRNSBlock Admission return
3rd Apr 20187:00 amRNSLicense Agreement Extension
28th Mar 20187:00 amRNSNotice of Results
22nd Mar 20181:18 pmRNSDirector/PDMR Shareholding
15th Mar 20184:40 pmRNSSecond Price Monitoring Extn
15th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Feb 20187:00 amRNSTrading Update
10th Nov 201710:11 amRNSHolding(s) in Company
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
27th Oct 201711:30 amRNSHolding(s) in Company
27th Oct 201711:30 amRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSHolding(s) in Company
20th Oct 201712:58 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSGCLP Accreditation and Trading Update
3rd Oct 20172:25 pmRNSBlock Admission Return
1st Sep 201712:08 pmRNSIssue of Equity
1st Aug 20177:00 amRNSDirectorate Changes
25th Jul 20177:00 amRNSInterim results for the 6 months to 30 June 2017
11th Jul 201712:00 pmRNSNotice of Results
30th Jun 201710:31 amRNSHolding(s) in Company
30th Jun 20177:00 amRNSStroke Diagnostic- Research Milestone Achieved
12th Jun 20177:00 amRNSNew Registered Address
8th Jun 20174:40 pmRNSSecond Price Monitoring Extn
8th Jun 20174:35 pmRNSPrice Monitoring Extension
15th May 20177:00 amRNSDirector/PDMR Shareholding
10th May 201710:09 amRNSDirector/PDMR Shareholding
5th May 201712:30 pmRNSDirector/PDMR Shareholding
4th May 20172:23 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20174:58 pmRNSDirector/PDMR Shareholding
28th Apr 20174:54 pmRNSHolding(s) in Company
25th Apr 20171:34 pmRNSAGM Statement and Result of AGM
11th Apr 20177:00 amRNSDirector Dealing and Total Voting Rights
4th Apr 20175:00 pmRNSHolding(s) in Company
4th Apr 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.